Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Yazan Numan, MD, Zaid Abdel Rahman, MD, Justin Grenet, MD, Stephanie Boisclair, MD, Jan Philipp Bewersdorf, MD, Dylan Barth, PharmD, BCPS, Amer M. Zeidan, MBBS, MHS, Musa Yilmaz, MD, Shira Dinner, MD, Yehuda E. Deutsch, MD, Olga Frankfurt, MD, Mark Litzow, MD, Aref Al-Kali, MD, James M. Foran, MD, Lisa Z. Sproat, MD, Borko Jovanovic, PhD, Naval Daver, MD, Alexander E. Perl, MD, Jessica K. Altman, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-137251

Published: 2020

Journal Articles

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

Carlos Galvez, MD, Reem Karmali, MDMSc, Mehdi Hamadani, MD, Leo I. Gordon, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Valerie Nelson, MD MBA, Brett Alan Palmer, BS, Timothy S. Fenske, MD, Nirav N. Shah, MD, Deepa Jagadeesh, MDMPH, Andreas Klein, MD, Irene Helenowski, PhD, Borko Jovanovic, PhD, Adam M Petrich, MD, Andrew M. Evens, DO,MMSc, Barbara Pro, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-138532

Published: 2020

Journal Articles

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

William Pearse, MD, Barbara Pro, MD, Leo I. Gordon, MD, Reem Karmali, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Amir Behdad, MD, Andreas Klein, MD, Adam M. Petrich, MD, Borko Jovanovic, PhD, Sonali M. Smith, MD, Andrew G Evans, MD PhD

Blood (2019) 134 (Supplement_1): 351.

https://doi.org/10.1182/blood-2019-127390

Published: 2019

Journal Articles

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Andrew M Evens, DO,MSc, Ranjana H. Advani, MD, Michelle A. Fanale, MD, Sonali M. Smith, MD, Irene Helenowski, PhD, Borko Jovanovic, PhD, R. Gregory Bociek, MD, Andreas Klein, MD, Jane N. Winter, MD, Leo I. Gordon, MD, Paul A. Hamlin, MD

Blood (2017) 130 (Supplement 1): 733.

https://doi.org/10.1182/blood.V130.Suppl_1.733.733

Published: 2017

Journal Articles

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Blood (2014) 124 (15): 2354–2361.

https://doi.org/10.1182/blood-2014-05-578963

Published: 2014

Includes: Supplemental data

Journal Articles

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

Andrew M. Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Borko Jovanovic, PhD, Adam Cohen, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD

Blood (2012) 120 (21): 1642.

https://doi.org/10.1182/blood.V120.21.1642.1642

Published: 2012

Journal Articles

A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels

Andrew M. Evens, DO, MSc, Nahida Islam, MD, Kenneth R. Carson, MD, Victoria Browning, PhD, Chadi Nabhan, MD, FACP, Borko Jovanovic, PhD, Paul M. Barr, MD, Paolo F. Caimi, MD, Irene Helenowski, PhD, Stephanie A. Gregory, Jill Kolesar, PhD, Leo I. Gordon, MD

Blood (2012) 120 (21): 1640.

https://doi.org/10.1182/blood.V120.21.1640.1640

Published: 2012

Journal Articles

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Andrew M. Evens, Irene Helenowski, Erika Ramsdale, Chadi Nabhan, Reem Karmali, Britt Hanson, Benjamin Parsons, Scott Smith, Annette Larsen, June M. McKoy, Borko Jovanovic, Stephanie Gregory, Leo I. Gordon, Sonali M. Smith

Blood (2012) 119 (3): 692–695.

https://doi.org/10.1182/blood-2011-09-378414

Published: 2012

Includes: Supplemental data

Journal Articles

Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin’s Lymphoma

Neelima Vidula, MD, Borko Jovanovic, PhD, Jane N. Winter, MD, Jayesh Mehta, MD, Seema Singhal, MD, Stephanie F. Williams, MD, Olga Frankfurt, MD, Jessica K. Altman, MD, Joanne Monreal, AAS, Andrew M. Evens, DO, MSc, Leo I. Gordon, MD, FACP

Blood (2011) 118 (21): 4499.

https://doi.org/10.1182/blood.V118.21.4499.4499

Published: 2011

Journal Articles

Integration of Rituximab and Liposomal Doxorubicin (DOXIL®) Into CODOX-M/IVAC for HIV-Negative and HIV+ Adults with Untreated Burkitt's Lymphoma (BL): Results of a Prospective Multicenter Phase II Study

Andrew M. Evens, DO, MSc, Kenneth R. Carson, MD, Chadi Nabhan, MD, FACP, Borko Jovanovic, PhD, Paul Barr, MD, Lilia Gallot, Irene Helenowski, MS, Paolo F. Caimi, MD, Stephanie A. Gregory, MD, Leo I. Gordon, MD, FACP

Blood (2011) 118 (21): 2669.

https://doi.org/10.1182/blood.V118.21.2669.2669

Published: 2011

Journal Articles

Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up

Richard K. Burt, Robert M. Craig, Francesca Milanetti, Kathleen Quigley, Paula Gozdziak, Jurate Bucha, Alessandro Testori, Amy Halverson, Larissa Verda, Willem J. S. de Villiers, Borko Jovanovic, Yu Oyama

Blood (2010) 116 (26): 6123–6132.

https://doi.org/10.1182/blood-2010-06-292391

Published: 2010

Journal Articles

Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies

Jane N. Winter, M.D., Dawn Waterhouse, Ph.D., Richard Ahn, Haimei Chen, Leo I. Gordon, M.D., Borko Jovanovic, Ph.D., Marcel Bally, Ph.D., Thomas O’Halloran, Ph.D.

Blood (2008) 112 (11): 4989.

https://doi.org/10.1182/blood.V112.11.4989.4989

Published: 2008

Journal Articles

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Andrew M. Evens, DO, MS, Stewart Spies, MD, David Patton, MS, Irene Helenowski, MS, Borko Jovanovic, PhD, Sarah Miyata, RN, ACNP, Elizabeth Hamilton, RN, CNP, M. Wayne Saville, MD, Richard A. Miller, MD, Jane N. Winter, MD, Leo I. Gordon, MD

Blood (2007) 110 (11): 2558.

https://doi.org/10.1182/blood.V110.11.2558.2558

Published: 2007

Journal Articles

Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used

Yvonne Loh, Yu Oyama, Laisvyde Statkute, Kathleen Quigley, Kimberly Yaung, Elizabeth Gonda, Walter Barr, Borko Jovanovic, Robert Craig, Dusan Stefoski, Bruce Cohen, Richard K. Burt

Blood (2006) 109 (6): 2643.

https://doi.org/10.1182/blood-2006-07-035766

Published: 2006

Journal Articles

Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation–based conditioning regimen to prevent disease progression in patients with high disability scores

Richard K. Burt, Bruce A. Cohen, Eric Russell, Kenneth Spero, Akash Joshi, Yu Oyama, William J. Karpus, Kehuan Luo, Borko Jovanovic, Ann Traynor, Karyn Karlin, Dusan Stefoski, William H. Burns

Blood (2003) 102 (7): 2373–2378.

https://doi.org/10.1182/blood-2003-03-0877

Published: 2003

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin’s Lymphoma

Integration of Rituximab and Liposomal Doxorubicin (DOXIL®) Into CODOX-M/IVAC for HIV-Negative and HIV+ Adults with Untreated Burkitt's Lymphoma (BL): Results of a Prospective Multicenter Phase II Study

Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up

Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used

Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation–based conditioning regimen to prevent disease progression in patients with high disability scores

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only